Italia markets closed
FTSE MIB
33.629,21 -107,19 (-0,32%) Dow Jones
38.675,68 +450,02 (+1,18%) Nasdaq
16.156,33 +315,37 (+1,99%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
77,99 -0,96 (-1,22%) Bitcoin EUR
58.458,03 +3.284,41 (+5,95%)
ILMN Dec 2024 160.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
Alla chiusura: 10:18AM EDT
| Chiusura precedente | 10,30 |
| Aperto | 10,30 |
| Denaro | 5,50 |
| Lettera | 8,20 |
| Prezzo d'esercizio | 160,00 |
| Scadenza | 2024-12-20 |
| Min-Max giorno | 10,30 - 10,30 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 65 |
GlobeNewswireMyriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
Myriad can conduct prospective clinical trials using Illumina’s TruSight Oncology Comprehensive Investigational Use Only testSALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two key milestones in its strategic partnership with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, to advance and support clinical research for gene-based, targeted thera
© 2024 Yahoo. Tutti i diritti riservati.